Law firm flags Eli Lilly retatrutide suits for pharmacies and telehealth sellers
Buchanan Ingersoll & Rooney advises compounders, telemedicine companies and online retailers on exposure from Lilly's litigation over the unapproved incretin candidate.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 15 08:26 ETSource: Buchanan Ingersoll & Rooney PC
The wire
- 01A client advisory from Buchanan Ingersoll & Rooney PC addresses Eli Lilly's retatrutide lawsuits and what pharmacies, telemedicine companies and online retailers should know.
- 02Retatrutide is an investigational triple agonist with no FDA approval, leaving any sale or distribution channel exposed to enforcement and civil claims.
- 03The item is legal commentary rather than a court ruling; operators should read the underlying complaints and consult counsel on their own supply arrangements.
From the source
Read at bipc.comEli Lilly’s Retatrutide Lawsuits: What Pharmacies, Telemedicine Companies and Online Retailers Need to Know
